ClinicalTrials.gg
CompletedNCT02343120Updated Apr 28, 2022Results posted

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

A Phase 1/2 interventional study of Zanubrutinib in B-cell Malignancies, sponsored by BeiGene. Completed at 23 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-28.

Sponsored by BeiGene · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2014, registered Jan 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
385
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluated the safety, tolerability, pharmacokinetic profile and efficacy of BGB-3111 in participants with B-cell lymphoid malignancies.

02

Conditions studied

  • B-cell Malignancies
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years, voluntarily consented to the study.
  2. WHO classification defined B-lymphoid , with the exception of Burkitt lymphoma/leukemia, plasma cell myeloma, acute lymphoblastic leukemia, lymphoblastic lymphoma, and plasmablastic lymphoma.
  3. Requirement for treatment in the opinion of the investigator.
  4. Disease which has , or is refractory, following at least one , with no therapy of higher priority available.
  5. (ECOG) performance status of 0-2.
  6. Adequate hematologic function, as defined by neutrophils ≥ 1.0 x 10\^9/L and ≥ 50 x 10\^9/L; participants with neutrophils \< 1.0 x 10\^9/L due to marrow infiltration are allowed to receive growth factors to bring pre-treatment neutrophils to ≥ 1.0 x 10\^9/L.
  7. Adequate renal function, as defined by of ≥ 30 ml/min (as estimated by the Cockcroft-Gault equation or as measured by nuclear medicine scan or 24 hour urine collection).
  8. Adequate liver function, as defined by (AST) and alanine aminotransferase (ALT) ≤ 3 x (ULN), and ≤ 1.5 x ULN (unless documented Gilbert's syndrome).
  9. (INR) ≤ 1.5 and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN.
  10. Female participants of and non-sterile males must practice at least one of the following methods of with partner(s) throughout the study and for 90 days after discontinuing study drug: total abstinence from sexual intercourse, double-barrier contraception, IUD or hormonal contraceptive initiated at least 3 months prior to first dose of study drug.
  11. Male participants must not donate sperm from initial study drug administration, until 90 days after drug discontinuation.

Exclusion criteria

Exclusion Criteria:

  1. Current central nervous system (CNS) involvement by disease
  2. Current histologically transformed disease.
  3. Prior Bruton's tyrosine kinase (BTK) inhibitor treatment.
  4. stem cell transplantation within 6 months, or has active (GVHD) requiring ongoing .
  5. Receipt of the following treatment prior to first dose of zanubrutinib: given with anti-neoplastic intent within 7 days, chemotherapy or radiotherapy within 2 weeks, monoclonal antibody within 4 weeks.
  6. Not recovered from toxicity of any prior chemotherapy to grade ≤ 1.
  7. History of other active within 2 years of study entry, with exception of (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally (surgery or other modality) with curative intent.
  8. Uncontrolled systemic infection requiring parenteral anti-microbial therapy.
  9. Major surgery in the past 4 weeks.
  10. Known , or active or infection (detected positive by PCR).
  11. Cardiovascular disease resulting in function status of ≥ 3.
  12. Significant active renal, neurologic, psychiatric, hepatic or endocrinologic disease that in the investigator's opinion would adversely impact on his/her participating in the study.
  13. Inability to comply with study procedures.
  14. On medications which are cytochrome P450 (CYP) 3A inhibitors.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
385 participants (actual)

Study arms

  • Experimental
    Zanubrutinib

    Participants were administered up to 320 mg total daily dose of zanubrutinib until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up

    Drug: Zanubrutinib

Interventions

  • Oral administration by capsule

    Also known as: BGB-3111, Brukinsa

06

What researchers measure

Primary outcomes

  1. Part 1 and Part 2: Number of Participants With Adverse Events

    Number of participants with adverse events and serious adverse events, including clinically relevant physical examinations and laboratory measurements

    Time frame: Up to approximately 6 years and 7 months

  2. Part 1: Recommended Phase 2 Dose (RP2D) for Zanubrutinib

    RP2D for zanubrutinib was the maximum tolerated dose (MTD) or less, which was determined by testing increasing doses up to 320 mg QD

    Time frame: Month 9

Secondary outcomes

  1. Part 1 and Part 2: Area Under the Curve From Time 0 to the Last Sampling Time Point Within the Dose Interval (AUClast) of Zanubrutinib

    Time frame: Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours

  2. Part 1 and Part 2: Area Under the Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Zanubrutinib

    Time frame: Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours

  3. Part 1 and Part 2: Maximum Observed Plasma Concentration (Cmax) After Administration of Zanubrutinib

    Time frame: Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours

  4. Part 1 and Part 2: Maximum Observed Plasma Concentration (Cmax) After Administration of Zanubrutinib

    Time frame: Week 2 Day 1 pre-dose and 24 hours

  5. Part 1 and Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib

    Time frame: Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours

  6. Part 1 and Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib

    Time frame: Week 2 Day 1 pre-dose and 24 hours

  7. Part 1 and Part 2: Apparent Terminal Half-life (t1/2) of Zanubrutinib

    Time frame: Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours

  8. Part 1 and Part 2: Apparent Clearance (CL/F) of Zanubrutinib

    Time frame: Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours

  9. Part 1 and Part 2: Apparent Volume of Distribution of Zanubrutinib During the Terminal Phase (Vz/F)

    Time frame: Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours

  10. Part 1 and Part 2: Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with partial or complete response (CR), as assessed by the investigator. For CLL/SLL, ORR includes partial response (PR) with lymphocytosis (PR-L) or better (includes PR-L, PR, nodular PR or nPR and CR with incomplete marrow recovery or CRi) and for MW, ORR includes minor response or better. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).

    Time frame: Up to 6 years and 7 months

  11. Part 1 and Part 2: Complete Response Rate (CRR)

    CRR is defined as the percentage of participants who achieve a complete response, as assessed by the investigator. For CLL/SLL, CRR includes CRi or better. For WM, CRR includes very good partial response (VGPR) or better. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).

    Time frame: Up to 6 years and 7 months

  12. Part 1 and Part 2: Partial Response (PR) or Better

    PR or better is defined as the percentage of participants who achieve a partial response or better, as assessed by the investigator. For CLL/SLL, includes PR, nPR, CRi, CR and for WM includes PR, VGPR, and CR. Efficacy results are reported for the B-cell malignancy subtypes chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Waldenström macroglobulinemia (WM).

    Time frame: Up to 6 years and 7 months

  13. Part 1 and Part 2: Progression-free Survival (PFS)

    PFS is defined as the time from the first dose date of study drug to the date of the earliest occurrence of progressive disease or death due to any cause, whichever occurs first. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).

    Time frame: Up to 6 years and 7 months

  14. Part 1 and Part 2: Overall Survival (OS)

    OS is defined as the time from the date of the first dose to death due to any cause. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).

    Time frame: Up to 6 years and 7 months

  15. Part 1 and Part 2: Duration of Response (DOR)

    DOR for responders is defined as time from the date of the earliest qualifying response to the date of progressive disease or death for any cause, whichever occurs earlier. Efficacy results are reported for responders (defined as PR or better, except CLL/SLL and WM) in each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; PR with lymphocytosis or better), Waldenstrom macroglobulinemia (WM; minor response or better), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).

    Time frame: Up to 6 years and 7 months

  16. Number of Participants With Greater Than 75% Bruton's Tyrosine Kinase (BTK) Occupancy

    Number of participants with greater than 75% BTK occupancy of zanubrutinib in peripheral blood mononuclear cells (PBMCs)

    Time frame: Week 1 Day 1 (W1D1) predose, W1D1 4 hours, W1D2 24 hours, W1D3 predose, and W2D1 predose

07

Results

Posted Apr 27, 2022

Participant flow

The study was conducted in 2 parts. The dose escalation part (Part 1) determined the recommended phase 2 dose (RP2D) and regimen and the dose expansion part (Part 2) further characterized the safety and efficacy at the RP2D.

Part 1: Dose Escalation
Participant flow — Part 1: Dose Escalation
MilestonePart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QD
Started34541
Completed00000
Not completed34541
Withdrew: Sponsor decision12320
Withdrew: Death12221
Withdrew: Lost to follow-up10000
Part 2: Expansion
Participant flow — Part 2: Expansion
MilestonePart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QD
Started00027494
Completed00000
Not completed00027494
Withdrew: Sponsor decision00016567
Withdrew: Death0007417
Withdrew: Withdrawal by subject000282
Withdrew: Lost to follow-up00052
Withdrew: Other00015
Withdrew: Adverse event00011

Outcome measures

PrimaryPart 1 and Part 2: Number of Participants With Adverse Events

Number of participants with adverse events and serious adverse events, including clinically relevant physical examinations and laboratory measurements

Time frame:
Up to approximately 6 years and 7 months
Reported as:
Count of participants · Participants
Part 1 and Part 2: Number of Participants With Adverse Events
ParticipantsPart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDParts 1 and 2: 160 mg BIDParts 1 and 2: 320 mg QD
At least one treatment-emergent adverse event34527494
Serious adverse events12315745
PrimaryPart 1: Recommended Phase 2 Dose (RP2D) for Zanubrutinib

RP2D for zanubrutinib was the maximum tolerated dose (MTD) or less, which was determined by testing increasing doses up to 320 mg QD

Time frame:
Month 9
Reported as:
Number · milligrams
Part 1: Recommended Phase 2 Dose (RP2D) for Zanubrutinib
milligramsPart 1: Zanubrutinib
Part 1: Recommended Phase 2 Dose (RP2D) for Zanubrutinib320
SecondaryPart 1 and Part 2: Area Under the Curve From Time 0 to the Last Sampling Time Point Within the Dose Interval (AUClast) of Zanubrutinib
Time frame:
Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Reported as:
Geometric mean · nanograms/milliliters*hour
Part 1 and Part 2: Area Under the Curve From Time 0 to the Last Sampling Time Point Within the Dose Interval (AUClast) of Zanubrutinib
nanograms/milliliters*hourPart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDParts 1 and 2: 160 mg BIDParts 1 and 2: 320 mg QD
Part 1 and Part 2: Area Under the Curve From Time 0 to the Last Sampling Time Point Within the Dose Interval (AUClast) of Zanubrutinib274.7 ± 47.8436.8 ± 103.51480 ± 53.01132 ± 61.12281 ± 60.5
SecondaryPart 1 and Part 2: Area Under the Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Zanubrutinib
Time frame:
Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Reported as:
Geometric mean · nanograms/milliliters*hour
Part 1 and Part 2: Area Under the Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Zanubrutinib
nanograms/milliliters*hourPart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QD
Part 1 and Part 2: Area Under the Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Zanubrutinib301.1 ± 51.5460.0 ± 100.61505 ± 52.71253 ± 59.02538 ± 47.8
SecondaryPart 1 and Part 2: Maximum Observed Plasma Concentration (Cmax) After Administration of Zanubrutinib
Time frame:
Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Reported as:
Geometric mean · nanograms/milliliter
Part 1 and Part 2: Maximum Observed Plasma Concentration (Cmax) After Administration of Zanubrutinib
nanograms/milliliterPart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QD
Part 1 and Part 2: Maximum Observed Plasma Concentration (Cmax) After Administration of Zanubrutinib86.0 ± 46.6125 ± 77.6397 ± 76.1304 ± 63.8566 ± 65.6
SecondaryPart 1 and Part 2: Maximum Observed Plasma Concentration (Cmax) After Administration of Zanubrutinib
Time frame:
Week 2 Day 1 pre-dose and 24 hours
Reported as:
Geometric mean · nanograms/milliliter
Part 1 and Part 2: Maximum Observed Plasma Concentration (Cmax) After Administration of Zanubrutinib
nanograms/milliliterPart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QD
Part 1 and Part 2: Maximum Observed Plasma Concentration (Cmax) After Administration of Zanubrutinib75.7 ± 36.2169 ± 50.0387 ± 60.7299 ± 56.1533 ± 55.0
SecondaryPart 1 and Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib
Time frame:
Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Reported as:
Median · Hours
Part 1 and Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib
HoursPart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QD
Part 1 and Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib1.00 (0.50 to 1.98)2.00 (1.17 to 2.00)1.92 (0.93 to 2.08)2.00 (0.83 to 8.00)2.00 (0.72 to 3.08)
SecondaryPart 1 and Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib
Time frame:
Week 2 Day 1 pre-dose and 24 hours
Reported as:
Median · Hours
Part 1 and Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib
HoursPart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QD
Part 1 and Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib2.00 (2.00 to 2.00)2.50 (1.08 to 3.00)2.00 (1.00 to 3.17)2.00 (0.53 to 6.00)2.00 (0.33 to 6.00)
SecondaryPart 1 and Part 2: Apparent Terminal Half-life (t1/2) of Zanubrutinib
Time frame:
Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Reported as:
Geometric mean · Hours
Part 1 and Part 2: Apparent Terminal Half-life (t1/2) of Zanubrutinib
HoursPart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QD
Part 1 and Part 2: Apparent Terminal Half-life (t1/2) of Zanubrutinib1.94 ± 28.51.97 ± 29.83.87 ± 24.92.73 ± 60.23.30 ± 61.2
SecondaryPart 1 and Part 2: Apparent Clearance (CL/F) of Zanubrutinib
Time frame:
Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Reported as:
Geometric mean · Liters/hour
Part 1 and Part 2: Apparent Clearance (CL/F) of Zanubrutinib
Liters/hourPart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QD
Part 1 and Part 2: Apparent Clearance (CL/F) of Zanubrutinib133 ± 51.5174 ± 100.6106 ± 52.7128 ± 59.4126 ± 47.8
SecondaryPart 1 and Part 2: Apparent Volume of Distribution of Zanubrutinib During the Terminal Phase (Vz/F)
Time frame:
Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Reported as:
Geometric mean · Liters
Part 1 and Part 2: Apparent Volume of Distribution of Zanubrutinib During the Terminal Phase (Vz/F)
LitersPart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QD
Part 1 and Part 2: Apparent Volume of Distribution of Zanubrutinib During the Terminal Phase (Vz/F)371 ± 47.5494 ± 78.9593 ± 61.6530 ± 70.0600 ± 97.6
SecondaryPart 1 and Part 2: Overall Response Rate (ORR)

ORR is defined as the percentage of participants with partial or complete response (CR), as assessed by the investigator. For CLL/SLL, ORR includes partial response (PR) with lymphocytosis (PR-L) or better (includes PR-L, PR, nodular PR or nPR and CR with incomplete marrow recovery or CRi) and for MW, ORR includes minor response or better. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).

Time frame:
Up to 6 years and 7 months
Reported as:
Number · Percentage of participants
Part 1 and Part 2: Overall Response Rate (ORR)
Percentage of participantsPart 1 and Part 2: Overall
CLL/SLL95.2 (89.8 to 98.2)
WM95.9 (88.5 to 99.1)
MCL82.5 (70.1 to 91.3)
MZL85.0 (62.1 to 96.8)
FL36.4 (20.4 to 54.9)
DLBCL42.2 (27.7 to 57.8)
RT61.5 (31.6 to 86.1)
HCL58.3 (27.7 to 84.8)
SecondaryPart 1 and Part 2: Complete Response Rate (CRR)

CRR is defined as the percentage of participants who achieve a complete response, as assessed by the investigator. For CLL/SLL, CRR includes CRi or better. For WM, CRR includes very good partial response (VGPR) or better. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).

Time frame:
Up to 6 years and 7 months
Reported as:
Number · Percentage of participants
Part 1 and Part 2: Complete Response Rate (CRR)
Percentage of participantsPart 1 and Part 2: Overall
CLL/SLL16.8 (10.7 to 24.5)
WM46.6 (34.8 to 58.6)
MCL28.1 (17.0 to 41.5)
MZL20.0 (5.7 to 43.7)
FL18.2 (7.0 to 35.5)
DLBCL24.4 (12.9 to 39.5)
RT15.4 (1.9 to 45.4)
HCL16.7 (2.1 to 48.4)
SecondaryPart 1 and Part 2: Partial Response (PR) or Better

PR or better is defined as the percentage of participants who achieve a partial response or better, as assessed by the investigator. For CLL/SLL, includes PR, nPR, CRi, CR and for WM includes PR, VGPR, and CR. Efficacy results are reported for the B-cell malignancy subtypes chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Waldenström macroglobulinemia (WM).

Time frame:
Up to 6 years and 7 months
Reported as:
Number · Percentage of participants
Part 1 and Part 2: Partial Response (PR) or Better
Percentage of participantsPart 1 and Part 2: Overall
CLL/SLL92.0 (85.8 to 96.1)
WM82.2 (71.5 to 90.2)
SecondaryPart 1 and Part 2: Progression-free Survival (PFS)

PFS is defined as the time from the first dose date of study drug to the date of the earliest occurrence of progressive disease or death due to any cause, whichever occurs first. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).

Time frame:
Up to 6 years and 7 months
Reported as:
Median · Months
Part 1 and Part 2: Progression-free Survival (PFS)
MonthsPart 1 and Part 2: Overall
CLL/SLL61.4 (55.2 to NA)
WMNA (48.9 to NA)
MCL27.6 (15.4 to 45.5)
MZLNA (17.1 to NA)
FL10.4 (7.7 to 22.9)
DLBCL4.1 (2.1 to 5.6)
RT17.3 (2.8 to NA)
HCLNA (28.7 to NA)
SecondaryPart 1 and Part 2: Overall Survival (OS)

OS is defined as the time from the date of the first dose to death due to any cause. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).

Time frame:
Up to 6 years and 7 months
Reported as:
Median · Months
Part 1 and Part 2: Overall Survival (OS)
MonthsPart 1 and Part 2: Overall
CLL/SLLNA (NA to NA)
WMNA (NA to NA)
MCLNA (27.2 to NA)
MZLNA (NA to NA)
FLNA (37.3 to NA)
DLBCL14.7 (5.5 to 24.8)
RT29.3 (4.2 to NA)
HCLNA (26.6 to NA)
SecondaryPart 1 and Part 2: Duration of Response (DOR)

DOR for responders is defined as time from the date of the earliest qualifying response to the date of progressive disease or death for any cause, whichever occurs earlier. Efficacy results are reported for responders (defined as PR or better, except CLL/SLL and WM) in each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; PR with lymphocytosis or better), Waldenstrom macroglobulinemia (WM; minor response or better), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).

Time frame:
Up to 6 years and 7 months
Reported as:
Median · Months
Part 1 and Part 2: Duration of Response (DOR)
MonthsPart 1 and Part 2: Overall
CLL/SLL58.6 (52.6 to NA)
WMNA (31.34 to NA)
MCL28.2 (16.2 to NA)
MZLNA (6.5 to NA)
FLNA (8.3 to NA)
DLBCL14.2 (2.8 to 26.2)
RT25.9 (5.9 to NA)
HCLNA (NA to NA)
SecondaryNumber of Participants With Greater Than 75% Bruton's Tyrosine Kinase (BTK) Occupancy

Number of participants with greater than 75% BTK occupancy of zanubrutinib in peripheral blood mononuclear cells (PBMCs)

Time frame:
Week 1 Day 1 (W1D1) predose, W1D1 4 hours, W1D2 24 hours, W1D3 predose, and W2D1 predose
Reported as:
Count of participants · Participants
Number of Participants With Greater Than 75% Bruton's Tyrosine Kinase (BTK) Occupancy
ParticipantsPart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QD
Number of Participants With Greater Than 75% Bruton's Tyrosine Kinase (BTK) Occupancy345209

Adverse events

Collected over Up to 6 years and 7 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: 40 mg QD1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Part 1: 80 mg QD2/4 (50%)2/4 (50%)4/4 (100%)
Part 1: 160 mg QD2/5 (40%)3/5 (60%)5/5 (100%)
Part 1 and Part 2: 160 mg BID76/278 (27.3%)157/278 (56.5%)273/278 (98.2%)
Part 1 and Part 2: 320 mg QD19/95 (20%)45/95 (47.4%)94/95 (98.9%)
Most frequent serious events
Showing 10 of 231
Most frequent serious events
EventPart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QD
Abdominal sepsisInfections and infestations1/30/40/50/2780/95
Complicated appendicitisInfections and infestations1/30/40/50/2780/95
HeadacheNervous system disorders1/30/40/50/2780/95
DyspnoeaRespiratory, thoracic and mediastinal disorders1/30/40/53/2781/95
CellulitisInfections and infestations0/31/40/59/2783/95
Renal artery thrombosisRenal and urinary disorders0/31/40/50/2780/95
PyrexiaGeneral disorders0/30/41/59/2783/95
Lower respiratory tract infectionInfections and infestations0/30/41/53/2780/95
PneumoniaInfections and infestations0/30/41/526/2786/95
Lentigo malignaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/41/50/2780/95
Most frequent other events
Showing 10 of 190
Most frequent other events
EventPart 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QD
Back painMusculoskeletal and connective tissue disorders0/33/40/534/27823/95
DiarrhoeaGastrointestinal disorders2/32/40/577/27823/95
Upper respiratory tract infectionInfections and infestations2/32/42/5106/27846/95
CoughRespiratory, thoracic and mediastinal disorders2/31/40/579/27821/95
AnaemiaBlood and lymphatic system disorders0/31/43/539/2788/95
NauseaGastrointestinal disorders1/32/41/545/27818/95
VomitingGastrointestinal disorders1/32/40/529/2786/95
PyrexiaGeneral disorders1/32/40/536/2785/95
HeadacheNervous system disorders0/32/42/546/27818/95
ContusionInjury, poisoning and procedural complications1/31/42/597/27839/95

Baseline characteristics

The Safety Analysis Set included all participants who received ≥ 1 dose of study drug

Age, Continuous
Age, Continuous(Years)Part 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QDTotal
Mean62.7 ± 9.4562.3 ± 14.3872.6 ± 8.8866.4 ± 11.2165.8 ± 11.2466.3 ± 11.19
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QDTotal
Female1118620109
Male23419275276
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: 40 mg QDPart 1: 80 mg QDPart 1: 160 mg QDPart 1 and Part 2: 160 mg BIDPart 1 and Part 2: 320 mg QDTotal
White24520587303
Asian10047553
Black or African American000415
Native Hawaiians or other Pacific Islanders000202
Multiple000101
Not Reported000101
Other00018220
08

Study locations

23 sites
  • Banner MD Anderson Cancer Centre
    Gilbert, Arizona 85234, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic
    Rochester, Minnesota 55901, United States
  • M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • Concord Repatriation General Hospital
    Concord, New South Wales, Australia
  • St George Hospital
    Sydney, New South Wales, Australia
  • Westmead Hospital
    Westmead, New South Wales, Australia
  • Princess Alexandra Hospital
    Brisbane, Queensland, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania, Australia
  • Monash Health
    Clayton, Victoria, Australia
  • Austin Health
    Heidelberg, Victoria, Australia
  • St Vincent's Hospital
    Melbourne, Victoria, Australia
  • Peter MacCallum Cancer Centre, East Melbourne
    Parkville, Victoria 3050, Australia
  • Melbourne Health
    Parkville, Victoria, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia, Australia
  • Policlinico S.Orsola Malpighi, AOU di Bologna
    Bologna, Italy
  • Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda
    Milano, Italy
  • Dong-A University Medical Centre
    Busan, Korea, Republic of
  • Inje University Busan Paik Hospital
    Busan, Korea, Republic of
  • National Cancer Center
    Goyang-si, Korea, Republic of
  • Samsung Medical Center
    Seoul, Korea, Republic of
  • North Shore Hospital
    Auckland, New Zealand
  • Derriford Hospital
    Plymouth, Devon, United Kingdom
09

References and documents

Publications

  • Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019 Sep 12;134(11):851-859. doi: 10.1182/blood.2019001160. Epub 2019 Jul 24. PubMed 31340982 ↗
  • Trotman J, Opat S, Gottlieb D, Simpson D, Marlton P, Cull G, Munoz J, Tedeschi A, Roberts AW, Seymour JF, Atwal SK, Yu Y, Novotny W, Holmgren E, Tan Z, Hilger JD, Huang J, Tam CS. Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up. Blood. 2020 Oct 29;136(18):2027-2037. doi: 10.1182/blood.2020006449. Erratum In: Blood. 2021 Feb 25;137(8):1131. doi: 10.1182/blood.2021010665. PubMed 32698195 ↗
  • C.S. Tam M. Wang D. Simpson S. Opat G. Cull J. Munoz T.J. Phillips W. Kim S. Atwal R. Wei J. Huang R. Elstrom J. Trotman. UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111). Hematological Oncology. 2019; 37(S2) DOI: https://doi.org/10.1002/hon.55_2630
  • Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS. Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol. 2022 Mar;196(5):1209-1218. doi: 10.1111/bjh.17994. Epub 2021 Dec 16. PubMed 34915592 ↗
  • Xu W, Yang S, Tam CS, Seymour JF, Zhou K, Opat S, Qiu L, Sun M, Wang T, Trotman J, Pan L, Gao S, Zhou J, Zhou D, Zhu J, Song Y, Hu J, Feng R, Huang H, Su D, Shi M, Li J. Zanubrutinib Monotherapy for Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies. Adv Ther. 2022 Sep;39(9):4250-4265. doi: 10.1007/s12325-022-02238-7. Epub 2022 Jul 28. PubMed 35900694 ↗
  • Phillips T, Chan H, Tam CS, Tedeschi A, Johnston P, Oh SY, Opat S, Eom HS, Allewelt H, Stern JC, Tan Z, Novotny W, Huang J, Trotman J. Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2022 Jun 14;6(11):3472-3479. doi: 10.1182/bloodadvances.2021006083. PubMed 35390135 ↗
  • Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, Kim WS, Rule S, Atwal SK, Wei R, Novotny W, Huang J, Wang M, Trotman J. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021 Jun 22;5(12):2577-2585. doi: 10.1182/bloodadvances.2020004074. PubMed 34152395 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2014 to primary completion in Mar 2021, 78 months.

Results were first posted in Apr 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2015
First posted
Jan 21, 2015
StartActual
Sep 4, 2014
Primary completionActual
Mar 31, 2021
CompletionActual
Mar 31, 2021
Results first posted
Apr 27, 2022
Last update
Apr 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02343120
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jan 21, 2015
Start date
Sep 4, 2014
Primary completion
Mar 31, 2021
Completion
Mar 31, 2021
Results posted
Apr 27, 2022
Last update
Apr 28, 2022

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion